• Johnson & Johnson outlined more than 20 oncology studies for ASCO 2026, with several results scheduled for future presentation at meeting.
• Late-breaking Phase 3 PROTEUS readout for ERLEADA is set to open ASCO plenary, positioning perioperative use around prostate surgery as potential practice-changing approach for high-risk localized or locally advanced prostate cancer.
• Phase 3 MajesTEC-9 findings for TECVAYLI are slated for presentation, supporting earlier use in multiple myeloma and reinforcing regimen as candidate new standard of care as early as second line.
• Pivotal OrigAMI-4 results evaluating RYBREVANT FASPRO in recurrent or metastatic head and neck cancer will be presented, with data framed as supportive of a potential shift in treatment for patients previously treated with immunotherapy and chemotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on April 29, 2026, and is solely responsible for the information contained therein.